Pancreatic Lesions in von Hippel-Lindau Disease? A Systematic Review and Meta-synthesis of the Literature

被引:83
作者
Charlesworth, Michael [1 ]
Verbeke, Caroline S. [2 ]
Falk, Gavin A. [3 ]
Walsh, Matthew [3 ]
Smith, Andrew M. [1 ]
Morris-Stiff, Gareth [1 ]
机构
[1] St James Univ Hosp, Pancreat Surg Unit, Leeds LS9 7TF, W Yorkshire, England
[2] Karolinska Inst, Stockholm, Sweden
[3] Cleveland Clin, Dept Surg, Sect Surg Oncol HPB, Cleveland, OH 44106 USA
关键词
Pancreas; von Hippel-Lindau disease; CENTRAL-NERVOUS-SYSTEM; RENAL-CELL CARCINOMA; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; MANAGEMENT; INVOLVEMENT; METASTASIS; CANCER; HEMANGIOBLASTOMAS; MANIFESTATIONS;
D O I
10.1007/s11605-012-1847-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
von Hippel-Lindau (vHL) disease is a rare condition that leads to characteristic lesions within many different body systems. Pancreatic manifestations of vHL cover a wide spectrum of pathologies, and thus, accurate characterization and management is critical. A comprehensive and systematic text word and MeSH search of the medical literature was performed to identify studies where information regarding the prevalence, clinical characteristics, and management recommendations could be extracted. Eleven studies were identified but 2 studies utilized the same data set. Of the 10 remaining studies, a total of 1,442 patients with vHL were available for analysis. Four hundred and twenty patients were examined for any type of pancreatic lesion, 362 for simple cysts or serous cystadenomas (SCAs), and 1,442 for neuroendocrine tumors (NETs). Of the 420 assessed for any pancreatic manifestation of vHL, 252 (60%) had a pancreatic lesion identified. Simple cysts that present as the sole manifestation of pancreatic disease were common and found in 169 of 362 (47%) patients. These are usually asymptomatic and do not normally require intervention. SCAs were reported in 39 of 362 (11%) patients and followed a similar benign course; resection is acceptable in symptomatic patients. NETs were identified in 211 of 1,442 (15%) patients, and 27 of 1,442 (2%) lesions behaved malignantly. Management of NETs depends on size, doubling time, and underlying genetics. Renal cell carcinoma is a characteristic in vHL, but there were no cases of pancreatic metastases identified from the included studies. Adenocarcinomas of the pancreas are not pathogenically linked to vHL. This review highlights the wide spectrum and high prevalence of pancreatic lesions in vHL. Simple cysts and SCAs are benign, but NETs require careful observation due to their malignant potential.
引用
收藏
页码:1422 / 1428
页数:7
相关论文
共 47 条
[1]  
[Anonymous], A VONGRAFES ARCH OPT
[2]   Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs) [J].
Blansfield, Joseph A. ;
Choyke, Lynda ;
Morita, Shane Y. ;
Choyke, Peter L. ;
Pingpank, James F. ;
Alexander, H. Richard ;
Seidel, Geoffrey ;
Shutack, Yvonne ;
Yuldasheva, Nargiza ;
Eugeni, Michelle ;
Bartlett, David L. ;
Glenn, Gladys M. ;
Middelton, Lindsay ;
Linehan, W. Marston ;
Libutti, Steven K. .
SURGERY, 2007, 142 (06) :814-818
[3]   Pancreatic metastases from renal cell carcinoma in von Hippel-Lindau disease [J].
Chambers, TP ;
Fishman, EK ;
Hruban, RH .
CLINICAL IMAGING, 1997, 21 (01) :40-42
[4]   Management of pancreatic lesions in von Hippel-Lindau disease [J].
Cheng, TY ;
Su, CH ;
Shyr, YM ;
Lui, WY .
WORLD JOURNAL OF SURGERY, 1997, 21 (03) :307-312
[5]   Abdominal visceral lesions in von Hippel-Lindau disease: Incidence and clinical behavior of pancreatic and adrenal lesions at a single center [J].
Delman, KA ;
Shapiro, SE ;
Jonasch, EW ;
Lee, JE ;
Curley, SA ;
Evans, DB ;
Perrier, ND .
WORLD JOURNAL OF SURGERY, 2006, 30 (05) :665-669
[6]   CHARACTERIZATION OF THE VHL TUMOR-SUPPRESSOR GENE-PRODUCT - LOCALIZATION, COMPLEX-FORMATION, AND THE EFFECT OF NATURAL INACTIVATING MUTATIONS [J].
DUAN, DR ;
HUMPHREY, JS ;
CHEN, DYT ;
WENG, YK ;
SUKEGAWA, J ;
LEE, S ;
GNARRA, JR ;
LINEHAN, WM ;
KLAUSNER, RD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (14) :6459-6463
[7]   CENTRAL-NERVOUS-SYSTEM INVOLVEMENT IN VONHIPPEL-LINDAU DISEASE [J].
FILLINGKATZ, MR ;
CHOYKE, PL ;
OLDFIELD, E ;
CHARNAS, L ;
PATRONAS, NJ ;
GLENN, GM ;
GORIN, MB ;
MORGAN, JK ;
LINEHAN, WM ;
SEIZINGER, BR ;
ZBAR, B .
NEUROLOGY, 1991, 41 (01) :41-46
[8]   Management of von Hippel-Lindau-associated kidney cancer [J].
Grubb, RL ;
Choyke, PL ;
Pinto, PA ;
Linehan, WM ;
Walther, MM .
NATURE CLINICAL PRACTICE UROLOGY, 2005, 2 (05) :248-255
[9]   Pancreatic involvement in von Hippel-Lindau disease [J].
Hammel, PR ;
Vilgrain, V ;
Terris, B ;
Penfornis, A ;
Sauvanet, A ;
Correas, JM ;
Chauveau, D ;
Balian, A ;
Beigelman, C ;
O'Toole, D ;
Bernades, P ;
Ruszniewski, P ;
Richard, S .
GASTROENTEROLOGY, 2000, 119 (04) :1087-1095
[10]   VON HIPPEL-LINDAU DISEASE - CLINICAL AND PATHOLOGICAL MANIFESTATIONS IN 9 FAMILIES WITH 50 AFFECTED MEMBERS [J].
HORTON, WA ;
WONG, V ;
ELDRIDGE, R .
ARCHIVES OF INTERNAL MEDICINE, 1976, 136 (07) :769-777